Accolade Welcomes Noom to Trusted Partner Ecosystem
Accolade Welcomes Noom to Trusted Partner Ecosystem
The partnership combines Noom's best-in-class content and coaching with Accolade's
advanced primary care physicians
該合作伙伴關係將 Noom 的一流內容和指導與 Accolade 的合作相結合
高級初級保健醫生
SEATTLE, May 21, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) announced today that Noom has joined Accolade's Trusted Partner Ecosystem to provide customers with a comprehensive solution for weight loss and metabolic health, including support for GLP-1s and other anti-obesity medications. In addition to the standard integrated features that drive appropriate Trusted Partner utilization, Noom's clinical obesity management solution, Noom Med, will be powered by Accolade physicians extensively trained in weight loss protocols and advanced primary care. The addition of Noom to Accolade's partner ecosystem builds on Accolade's existing partnership in the metabolic space with Virta Health.
西雅圖，2024 年 5 月 21 日 /PRNewswire/ — Accolade, Inc.（納斯達克股票代碼：ACCD） 今天宣佈 那個 Noom 已加入 Accolade 的可信合作伙伴生態系統，爲客戶提供減肥和代謝健康的全面解決方案，包括支持 GLP-1 和其他抗肥胖藥物。除了推動適當利用可信合作伙伴的標準集成功能外，Noom 的臨床肥胖管理解決方案 Noom Med 還將由接受過減肥方案和高級初級保健方面廣泛培訓的 Accolade 醫生提供支持。將Noom加入Accolade的合作伙伴生態系統建立在Accolade與Virta Health在新陳代謝領域的現有合作伙伴關係的基礎上。
Accolade and Noom's partnership offers employers a comprehensive, evidence-based model with personalized offerings for an employer's entire population, including connecting higher-risk members with Accolade physicians. This partnership empowers employers to stem the rising healthcare costs associated with obesity and its many comorbid conditions – and to ensure increasingly in-demand GLP-1s are appropriately prescribed and those taking them supported clinically.
Accolade和Noom的合作爲僱主提供了一個全面的、基於證據的模式，爲僱主的全體員工提供個性化服務，包括將高風險成員與Accolade醫生聯繫起來。這種夥伴關係使僱主能夠遏制與肥胖及其多種合併症相關的醫療費用上漲，並確保對需求量不斷增加的GLP-1給予適當的處方併爲服用者提供臨床支持。
Noom leverages psychology and science to drive behavioral change. Noom's enterprise solutions provide personalized, tailored support for members' unique weight loss journeys. Through a combination of informative content, nutrition, activity tracking tools, coaching, and community, Noom has proven to help people suffering from obesity lose at least 10% of their body weight and keep it off - with 42% of users maintaining total weight loss for at least two years. Noom's strong brand recognition consistently generates on average an employee adoption rate of 25%, helping drive meaningful results across an employer's population.
Noom 利用心理學和科學來推動行爲改變。Noom 的企業解決方案爲會員獨特的減肥之旅提供個性化、量身定製的支持。通過將信息內容、營養、活動跟蹤工具、指導和社區相結合，Noom 已被證明可以幫助肥胖患者 減掉至少 10% 的體重 並堅持下去——42％的用戶至少可以保持兩年的總體減肥效果。Noom 強大的品牌知名度平均持續產生僱員 採用率爲 25%，有助於在僱主群體中取得有意義的結果。
"In May 2023, responding to the marked increase in anti-obesity medication adoption, Noom launched Noom Med to provide high-quality clinical support to those suffering from the chronic disease of obesity," said Noom's CEO, Geoff Cook. "We put rigorous clinical protocols and a sophisticated technology platform in place to facilitate integration between physician-led care teams and our valuable content and coaching. Accolade's proven track record in primary care and building longitudinal relationships sets them apart – we see them as an ideal partner with whom to grow together."
Noom首席執行官傑夫·庫克表示：“2023年5月，爲了應對抗肥胖藥物採用率的顯著增加，Noom推出了Noom Med，爲肥胖慢性病患者提供高質量的臨床支持。”“我們制定了嚴格的臨床協議和複雜的技術平台，以促進醫生領導的護理團隊與我們的寶貴內容和指導之間的整合。Accolade 在初級保健和建立縱向關係方面的良好記錄使他們與衆不同——我們將他們視爲共同成長的理想合作伙伴。”
When a member first engages with Noom, they'll complete a personalized assessment determining whether they're best served by (a) Noom Weight, a digital psychology-based weight management program, (b) Noom Diabetes Prevention Program, a tailored digital solution for those who show risk of diabetes - awarded full plus recognition by the CDC, or (c) Noom Med powered by Accolade, where Accolade physicians provide evidence-based obesity care that augments Noom's digital support. Non-GLP-1 anti-obesity medications are expected to be the initial course of action for nearly half of all participants. For more on the member experience, see here.
當會員首次接觸 Noom 時，他們將完成個性化評估，確定他們是否能獲得最佳服務：(a) Noom Weight，一項基於數字心理學的體重管理計劃；(b) Noom 糖尿病預防計劃，這是一項爲有糖尿病風險的人量身定製的數字解決方案（獲得美國疾病預防控制中心全額認可）；或 (c) 由 Accolade 提供支持的 Noom Med，Accolade 醫生在其中提供增強免疫力的循證肥胖護理 OM 的數字支持。預計非GLP-1抗肥胖藥物將成爲近一半參與者的初步行動方案。有關會員體驗的更多信息，請參閱 這裏。
"When a member goes to Noom Med powered by Accolade, we ensure that the right members are gaining access to GLP-1s or other anti-obesity treatment and that members are making the behavior and lifestyle changes necessary to, where appropriate, successfully taper off those medications," said Dr. James Wantuck, Accolade Chief Medical Officer. "Our customers and members will benefit from Accolade's physician-led model combined with Noom's best-in-class content, coaching, and community. This innovative combination will drive sustainable weight-loss outcomes and reduce inappropriate spending."
Accolade首席醫學官詹姆斯·旺塔克博士說：“當會員使用由Accolade提供支持的Noom Med時，我們會確保合適的會員獲得GLP-1或其他抗肥胖治療，並確保會員做出必要的行爲和生活方式改變，以便在適當的情況下成功減少這些藥物的使用。”“我們的客戶和會員將受益於 Accolade 以醫生爲主導的模式，再加上 Noom 一流的內容、指導和社區。這種創新的組合將推動可持續的減肥效果並減少不當支出。”
Obesity is a significant health and business challenge. Nationwide obesity rates have more than tripled since the 1960s, with the current estimated rate at 43%. Obesity is associated with a heightened risk of heart disease, type 2 diabetes, cancer, asthma, and other preventable health problems. Estimates put the annual medical costs related to obesity in the US at $173 billion, and employers are contending with a dramatic uptick in GLP-1 utilization, which has contributed to an 8.4% increase in pharmacy benefit costs.
Accolade's Trusted Partner Ecosystem Increases Digital Solution Engagement
Accolade 的可信合作伙伴生態系統提高了數字解決方案的參與度
Launched in 2019, Accolade's Trusted Partner Ecosystem accelerates the performance of digital health solutions to improve outcomes across valued categories for employers. Accolade's ecosystem currently consists of 18 partners across 11 categories.
Accolade's 於 2019 年推出值得信賴的合作伙伴生態系統 加快數字健康解決方案的性能，改善僱主在各個有價值類別中的結果。Accolade 的生態系統目前由 11 個類別的 18 個合作伙伴組成。
Benefits teams can confidently select from thoroughly vetted solutions and enjoy streamlined contracting and implementation. Through qualified referrals, Accolade drives more engagement with partner solutions, leading to exponentially better health outcomes and better value. Learn more here.
福利團隊可以放心地從經過全面審查的解決方案中進行選擇，並享受簡化的合同和實施流程。通過合格的轉診，Accolade 推動了與合作伙伴解決方案的更多互動，從而成倍地改善健康狀況和更高的價值。了解更多這裏。
About Accolade
關於 Accolade
Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinions, and best-in-class care navigation. These offerings are built on a platform engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedIn, X, Instagram, and Facebook.
Accolade（納斯達克股票代碼：ACCD）是一家個性化醫療保健公司，爲數百萬人及其家人提供卓越的醫療保健體驗，使他們能夠過上最健康的生活。Accolade 的僱主、健康計劃和消費者解決方案將虛擬初級保健和心理健康、專家醫療意見和一流的護理導航相結合。這些服務建立在專爲醫療而設計的平台之上，該平台旨在通過預測性地參與人口健康需求、提高療效和節省成本的主動護理以及解決獲得醫療服務和持續性方面的障礙。Accolade 一直獲得超過 90% 的消費者滿意度。欲了解更多信息，請訪問accolade.com。關注我們領英，X，Instagram，以及Facebook。
About Noom
關於 Noom
Noom is the digital healthcare company empowering people to live better, longer lives. Noom connects people to content, coaching, community, and clinicians to improve whole-person health. Noom also works with leading employers, health plans, and health systems, offering Noom Med, Noom GLP-1 Companion, Noom Weight, Noom Diabetes Prevention Program, and Noom Mood to millions of covered lives. The company has been awarded multiple grants from the National Institutes of Health and was the first mobile application to be recognized by the Centers for Disease Control and Prevention as a certified diabetes prevention program. With offices in New York City and Princeton, New Jersey, Noom has been named one of Inc.'s Best Places to Work, Quartz's Best Workplaces for Remote Workers, and Fortune's Best Workplaces in Technology. To learn more about Noom, visit noom.com.
Noom 是一家數字醫療保健公司，幫助人們過上更美好、更長壽的生活。Noom 將人們與內容、指導、社區和臨床醫生聯繫起來，以改善全人健康。Noom 還與領先者合作 僱主、健康計劃和衛生系統，爲數百萬受保人提供 Noom Med、Noom GLP-1 Companion、Noom Weight、Noom 糖尿病預防計劃和 Noom Mood。該公司已獲得美國國立衛生研究院的多項資助，並且是第一個被美國疾病控制與預防中心認可爲認證糖尿病預防計劃的移動應用程序。Noom 在紐約市和新澤西州普林斯頓設有辦事處，被評爲公司之一。最佳工作場所，Quartz的遠程工作者最佳工作場所，以及《財富》雜誌的科技領域最佳工作場所。要了解有關 Noom 的更多信息，請訪問noom.com。
View original content to download multimedia:https://www.prnewswire.com/news-releases/accolade-welcomes-noom-to-trusted-partner-ecosystem-302151148.html
SOURCE Accolade, Inc.
來源 Accolade, Inc.
Accolade Media Relations, media@accolade.com, Noom Media Relations, comms@noom.com
Accolade Media Relations，media@accolade.com，Noom 媒體關係，comms@noom.com
譯文內容由第三人軟體翻譯。